Stress-associated transient enlargement of pre-existing adrenal hyperplasia in 21-hydroxylase deficiency: a case report - Report - MDSpire

Stress-associated transient enlargement of pre-existing adrenal hyperplasia in 21-hydroxylase deficiency: a case report

  • By

  • Chengcheng Zheng

  • Lianling Zhao

  • Tao Chen

  • July 10, 2026

  • 0 min

Share

Clinical Report: Stress-Induced Temporary Increase in Adrenal Hyperplasia

Overview

This case study presents a 40-year-old man with 21-hydroxylase deficiency who exhibited significant bilateral adrenal enlargement following an acute upper respiratory infection. The adrenal volume decreased substantially after one month, suggesting a stress-induced compensatory response to increased cortisol demand.

Background

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is characterized by impaired cortisol production, leading to adrenal hyperplasia and hormonal imbalances. Understanding the effects of stress on adrenal morphology is crucial for managing patients with CAH, as stress can exacerbate existing conditions.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • A 40-year-old man with 21-hydroxylase deficiency showed marked bilateral adrenal enlargement after an upper respiratory infection.
  • Elevated ACTH levels (180 ng/L) and low cortisol levels (174 nmol/L) were noted upon admission.
  • Genetic testing confirmed a CYP21A2 I172N homozygous mutation.
  • Adrenal volume decreased from 61.06 cm3 to 33.47 cm3 within one month, indicating a 1.8-fold reduction.
  • The transient enlargement was hypothesized to be a compensatory response to increased cortisol demand due to stress.

Clinical Implications

Healthcare professionals should consider the impact of acute stressors on adrenal function in patients with CAH.

Conclusion

This case highlights the potential for stress-induced changes in adrenal morphology in patients with 21-hydroxylase deficiency.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. Author(s)/Org, Source, Year -- Title
  6. Author(s)/Org, Source, Year -- Title
  7. FDA Approves New Treatment for Congenital Adrenal Hyperplasia | FDA
  8. Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications | Endocrine Society
  9. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline - PMC
  10. FDA Approves New Treatment for Congenital Adrenal Hyperplasia | FDA

Original Source(s)

Related Content